Can An Orphan Drug Be Approved Without Clinical Trial?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committee will consider Orphan Europe's NDA for Carbaglu in NAGS deficiency, which is based on data from retrospective review of patient experience with carglumic acid